The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Treatment options for transplant-ineligibile HL patients
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses treatment options for transplant-ineligible Hodgkin lymphoma (HL) patients, highlighting the promise of targeted agents such as brentuximab vedotin, nivolumab and pembrolizumab, and the long-term benefits of these agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
